This report was first published by Endpoints News. To see the original version, click here
New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma in some patients, it may not be safer than the cell therapies engineered in a lab.
Compared to conventional CAR-T cell therapies, which have upended multiple myeloma treatment but are challenging to make and give, in vivo cell therapies are meant to be a simple infusion that instructs a patient’s own cells to fight disease.
您已阅读13%（575字），剩余87%（3944字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。